Latest Regulatory Approvals News

Diamond Infraco has extended its takeover offer for Atlas Arteria to 25 June 2026, waiving several key conditions and adjusting the timeline for regulatory updates.

Northern Star Resources acknowledges activist investor Elliott's stake and proposals, confirms ongoing CEO recruitment, and highlights progress on key projects while rejecting a sale process.

Amaero Ltd has obtained Federal Court approval to re-domicile to Delaware via schemes exchanging Australian shares and options for US HoldCo equivalents, marking a major structural shift.

Cokal Limited has secured regulatory approval to resume mining at its Bumi Barito Mineral project, with operations set to restart mid-June and a 10,000 MT coal shipment planned for late June.

Rox Resources has secured a fixed-cost EPC contract for its Youanmi processing plant while accelerating underground mining fronts and stockpile development, keeping first gold pour on track for mid-2027.

Peninsula Energy has executed a definitive agreement for a US$30 million senior secured convertible note facility with an affiliate of Soul Patts, advancing its financing strategy for the Lance Uranium Project in Wyoming.

The Supreme Court of Western Australia has approved Genesis Minerals’ acquisition of Magnetic Resources, setting a clear timetable for scheme implementation and ASX trading suspension.

Novo Resources has delivered a maiden inferred resource estimate for the Leven Star Reef within its Belltopper Gold Project, outlining 87,000 ounces of contained gold and setting the stage for further exploration and resource expansion.

Imugene’s off-the-shelf CAR T therapy azer-cel has won FDA Fast Track Designation for relapsed or refractory CLL/SLL and MZL, backed by compelling Phase 1b response rates.

Sunshine Metals has agreed to sell its Hodgkinson Project to EQ Resources for $250,000, freeing up capital and management bandwidth to accelerate gold production at Mt Moss and exploration at Sybil.

OncoSil Medical has cleared a major regulatory hurdle as its Humanitarian Device Exemption application nears FDA approval, while its TRIPP-FFX trial shows promising results combining OncoSil with standard chemotherapy for pancreatic cancer.

Qube Holdings confirms progress on regulatory approvals for its $5.20-per-share takeover scheme by Rubik Australia, with a shareholder meeting scheduled for June 16 and plans for a special dividend.